The company will supply vaccine in 10 and 20 vial presentations during Q2 CY2026 and CY2027, under an order worth $35.65 million (around Rs 315 crore). Panacea Biotec is engaged in the business of research, development, manufacture, and marketing of branded pharmaceutical formulations in India and international markets.
The company reported a consolidated net profit of Rs 4.05 crore in Q1 FY26 compared with net loss of Rs 15.80 crore in Q1 FY25. Net sales jumped 44.1% YoY to Rs 166.70 crore in Q1 FY26.
Powered by Capital Market - Live News